Cardiovascular and ANS
The CardioANS™ device is an FDA-cleared Class II medical device designed for assessing heart failure (HF), with a specific focus on arterial hardening, circulation, heart rate variability, and autonomic nervous system function.
Congestive heart failure is when your heart becomes so weak that it can't pump enough blood to meet your body's needs.
Identify Cardiovascular Risks
Diabetic Cardiomyopathy is a disorder of the heart muscle in people with diabetes. Diabetic cardiomyopathy is a condition where diabetes adversely affects the structure and function of the heart muscle. While traditional cardiovascular diseases are often associated with conditions like high blood pressure or atherosclerosis, diabetic cardiomyopathy occurs independently of these factors. Patients with diabetes Type 2 have up to a 74% increased risk of developing Heart Failure (HF), and diabetic patients with HF are 4x more likely to die than those without HF. Importantly, unrecognized HF is highly prevalent in Type 2 diabetics, with over one quarter (27.7%) of those over 60's having previously undiagnosed HF in one report. Therefore it is one, if not the, most important assessment to be measured for all Type 2 diabetic patients and people with 2 or more comorbidities.
The Framingham Study found that individuals with asymptomatic left ventricular systolic dysfunction (LVSD) at entry had a nearly 5X increase in the risk of developing symptomatic heart failure (HF) compared to those with normal left ventricular function.
Kannel WB, Gordon T, and National Heart Institute (U.S.) (1968) The Framingham study: An epidemiological investigation of cardiovascular disease. Bethesda, MD., United States. Department of Health, Education, and Welfare, National Institutes of Health.
Heart disease may go undiagnosed until symptoms of myocardial infarction, heart failure, or arrhythmia appear. The goal should be to prevent heart failure symptoms by screening at-risk patients for asymptomatic heart dysfunction and implementing cost-effective interventions in the early stages. Echo is the most common way to diagnose heart failure, but our CardioANS™ can provide an inexpensive early screening for all at-risk patients with a high reimbursement. Also, the cardiorenal axis is a new target for intervention in heart failure. Cardiorenal and metabolic comorbidities are common in most people with diabetes and obesity and the interdependent relationship between the heart and the kidneys is an increasingly important target for intervention in the treatment of heart failure, as addressing both organs together can lead to better outcomes for patients.
Our CardioANS™ test is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). The CardioANS™ graphs the heartbeat as it moves through systolic and diastolic cycles. It tracks deviations in fingertip pressure caused by flexible arteries and produces a tight, regular graph for stiff arteries. Using a proprietary algorithm, the device analyses arterial pulse wave variations and compares them against a large body of research to accurately assess arterial hardening.
Our CardioANS™ assessment measures the left ventricle and can be performed by a medical assistant to aid in diagnosing heart failure (HF), providing real-time results.
CVD & Long COVID-19
Post COVID-19 syndrome is a cluster of symptoms lasting many months after infection and may severely impacts a person for the rest of their life.
Long COVID-19 Consequences
COVID-19 can have implications for the cardiovascular system, particularly the left ventricle of the heart. Cardiomyopathy in COVID-19 patients refers to a condition where the heart muscle becomes inflamed and weakened due to the viral infection. Many people who have recovered from COVID-19 have reported experiencing lingering cardiovascular symptoms such as abnormal heartbeats, dizziness, and shortness of breath.
It's essential for individuals with long COVID, particularly those with cardiovascular symptoms, to be tested in the primary care setting to determine if there is should be more comprehensive imaging studies like echocardiograms to evaluate the structure and function of the left ventricle. Monitoring the left ventricle's health is crucial for developing targeted interventions and treatment plans to address the lingering cardiovascular effects of the virus.
Features of the tests:
3-minute non-invasive assessment
Measures the overall cardiovascular risk factors (heart attack and stroke)
Measures the left ventricle ejection and contraction power
Measures mental stress, physical stress, and resistance to stress
COVID-19 survivors, regardless of infection severity, are more likely to develop cardiovascular conditions such as heart failure or coronary disease within 30 days post-infection.
